Feature|Videos|May 23, 2025

Inside Experic: Revolutionizing CDMO & Clinical Packaging Services

Author(s)Dave Wood

Dave Wood, CEO at Experic, discusses how decades of expertise with advanced technologies helps pharmaceutical and biotech partners bring products to market faster.

Experic is a contract development and manufacturing organization (CDMO) that delivers integrated pharmaceutical solutions across the drug development lifecycle. With specialized expertise in complex formulations, including precision low-dose capsule filling and inhalation therapies, Experic supports clients from early development through global distribution. Its advanced facility and experienced team enable rapid project execution through customized manufacturing, packaging, and clinical supply services. By unifying these capabilities under one roof, Experic streamlines timelines, ensures product integrity, and accelerates time to market for both emerging biotech and large pharmaceutical companies.

Learn More About:

  1. Experic’s integrated CDMO capabilities and how they support end-to-end pharmaceutical development and distribution.
  2. The unique technologies and expertise that well positions Experic in complex drug formulation and clinical packaging.
  3. A unified approach to manufacturing, packaging, and logistics to reduce project timelines and ensure regulatory compliance.

Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.